Goldman Sachs Group Inc Horizon Therapeutics Public LTD CO Call Options Transaction History

Goldman Sachs Group Inc

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2023 May 14, 2024	BUY	$98.98 - $115.74 $45.5 Million - $53.2 Million	459,900 New	459,900 $53.2 Million
Q3 2023 Nov 14, 2023	SELL	$98.98 - $115.74 $83.9 Million - $98.1 Million	-847,900 Reduced 64.83%	459,900 $53.2 Million
Q2 2023 May 14, 2024	BUY	$96.34 - $112.38 $126 Million - $147 Million	1,307,800 New	1,307,800 $135 Million
Q2 2023 Aug 14, 2023	BUY	$96.34 - $112.38 $126 Million - $147 Million	1,307,800 New	1,307,800 $135 Million
Q4 2021 Feb 14, 2022	BUY	$98.56 - $119.91 $1.02 Million - $1.24 Million	10,300 New	10,300 $1.11 Million

2.07M

20K

Ticker HZNP
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 230,384,000
Description
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines ...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.